EphMRA Annual Conference 2019
25-27 June 2019 Warsaw, Poland
We are delighted to be sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland 25-27 June. Representing Research Partnership are Director and EphMRA Board Member Richard Head, Director Paula Coyle, and Associate Director Emilie Braund. Also in attendance will be Associate Director An-hwa Lee who sits on the EphMRA Learning and Development Committee, which plans to convene before the conference begins.
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.
Dan Coffin joins London Headquarters as Director
Research Partnership is delighted to welcome Dan Coffin who has joined the company’s global head office in London
Dan Coffin joins Research Partnership as Director for the EU region. Dan has over 18 years’ experience in the pharmaceutical sector, with particular interest in digital therapy and the growing health-tech arena. Dan brings experience from the agency side, strengthened by client-side roles at Roche and Johnson & Johnson. Most recently, Dan was employed at Illuminas where he established and ran their healthcare market research arm. He is an active industry contributor and has been a BHBIA Board director since 2013.
2015: a good year for psoriasis drug development?
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide.
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterised by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients’ quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other chronic illnesses. Although a number of treatment options exist for PsO, there continue to be significant unmet needs in the market
Central and Eastern Europe
An overview of the six most-commonly researched, largest pharmaceutical markets in CEE